Crinetics Pharmaceuticals (CRNX) Return on Capital Employed (2018 - 2026)

Crinetics Pharmaceuticals' Return on Capital Employed history runs 9 years deep, the most recent figure standing at 45.76% for Q1 2026.

• On a quarterly basis, Return on Capital Employed fell 1766.0% year-over-year to 45.76% in Q1 2026; TTM through Mar 2026 was 45.76%, a 1766.0% decrease from a year earlier, with the FY2025 full-year figure at 43.23%, down 849.0% from the prior year.
• Return on Capital Employed grew to 45.76% in Q1 2026 per CRNX's latest filing, from 48.02% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 28.1% in Q1 2025 and bottomed at 70.84% in Q2 2023.
• The 5-year median for Return on Capital Employed is 38.58% (2022), against an average of 41.52%.
• Across the five-year window, Return on Capital Employed sank 3226 bps in 2023 and soared 4004 bps in 2024, its largest moves.
• Year by year, Return on Capital Employed stood at 49.26% in 2022, then rose by 24 bps to 37.44% in 2023, then advanced by 20 bps to 30.09% in 2024, then tumbled by 60 bps to 48.02% in 2025, then rose by 5 bps to 45.76% in 2026.
• Per Business Quant, the three latest CRNX Return on Capital Employed figures stand at 45.76% (Q1 2026), 48.02% (Q4 2025), and 40.89% (Q3 2025).